
|Articles|February 1, 2022
Daily Medication Pearl: Bupropion (Aplenzin)
Author(s)Saro Arakelians, PharmD
Bupropion (Aplenzin) is an antidepressant that treats major depressive disorder and seasonal affective disorder.
Advertisement
Medication Pearl of the Day: Bupropion (Aplenzin)
Indication: Bupropion (Aplenzin) is an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD) and seasonal affective disorder (SAD). Periodically reevaluate long-term usefulness for the individual patient.
Insight:
- Dosing: Starting dose 174 mg once daily (equivalent to 150 mg bupropion HCl). Usual target dose 348 mg once daily (equivalent to 300 mg bupropion HCl).
- Dosage forms: Extended-release tablets 174 mg, 348 mg, and 522 mg.
- Adverse events: Most common adverse reactions are (incidence ≥5%; ≥2× placebo rate) dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, and rash.
- Mechanism of action: The mechanism of action of bupropion is unknown, as is the case with other antidepressants; however, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms.
- Manufacturer: Valeant Pharma
Sources:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5








































































































































